NUZ — Neurizon Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$62.62m
- AU$53.22m
Neurizon Therapeutics rises after US FDA lifts clinical hold on key therapy
Brief: Neurizon Therapeutics Raises A$5 Million At A$0.12 Per Share
Brief: Neurizon Therapeutics Seeks Trading Halt
Brief: Neurizon Therapeutics Posts Loss For Year Attributable A$16.6 Million
Australia's Neurizon Therapeutics jumps on licensing agreement with Elanco
Brief: Neurizon Therapeutics Enters Global Licensing Agreement With Elanco
Brief: NUZ-001 Shows Promise In Zebrafish Model Of Huntington's Disease
Brief: Neurizon Therapeutics Appoints Dan O’Connell As CFO
Brief: Neurizon Therapeutics Logs HY Loss Attributable A$7.3 Mln
Brief: Neurizon Therapeutics Says Got Guidance From FDA Placing IND Application For NUZ-001 Under Clinical Hold
Brief: Neurizon Therapeutics Says US Patent Granted For NUZ-001
Australia's Neurizon Therapeutics rise on US patent approval
Australia's Neurizon Therapeutics slides after FDA puts drug application on hold
Brief: Neurizon Therapeutics Says U.S. FDA Placed Co's Investigational New Drug Application Under Clinical Hold
Brief: Neurizon Files Ind Application To Support Healey Als Platform Trial
Australia's Neurizon Therapeutics surges on getting OMPD for ALS drug in Europe
Brief: Neurizon's NUZ-001 Reduces Aggregation Of Key ALS Disease Target TDP-43 In Preclinical Study
Brief: Neurizon Therapeutics Gets EMA's Positive Opinion On Orphan Medicinal Product Designation For NUZ-001
Australia's PharmAust rises on ALS treatment drug's entry into a trial